Discover open access scientific publications

Search, annotate, share and cite publications

Publications by R. Shiga

P1.01-41 a Phase 2 Study of DS-8201a in HER2-Overexpressing or -Mutated Advanced Non-Small-Cell Lung Cancer

Journal of Thoracic Oncology

English

Related publications

OA02.07 Updated Results of Phase 1 Study of DS-8201a in HER2-Expressing or –Mutated Advanced Non-Small-Cell Lung Cancer

Journal of Thoracic Oncology

English

P1.01-13 a Study of S-1 Plus Cisplatin in Patients With Advanced Non-Small-Cell Lung Cancer

Journal of Thoracic Oncology

English

P1.01-91 a Phase I Study of Fixed Dose Vinorelbine and Escalating Doses of Ifosfamide in First-Line Advanced Non-Small Cell Lung Cancer

Journal of Thoracic Oncology

English

P1.01-19 Efficacy of Tyrosine Kinase Inhibitors in EGFR Mutated Non-Small Cell Lung Cancer With Leptomeningeal Metastases

Journal of Thoracic Oncology

English

P1.01-71 Co-Mutations, Natural History, and Outcomes of BRAF-Mutated Non-Small Cell Lung Cancer at a Single Academic Cancer Center

Journal of Thoracic Oncology

English

P1.01-109 Phase I Study of Apatinib Plus Gefitinib as First-Line Therapy in Patients With EGFR Mutant Advanced Non-Small Cell Lung Cancer

Journal of Thoracic Oncology

English

P1.01-47 Phase I/Ii Trial of Dasatinib and Osimertinib in Patients With Advanced EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)

Journal of Thoracic Oncology

English

P1.01-32 a Multicenter, Open-Label, Phase II Trial of S-1 Plus Carboplatin in Advanced Non-Small Cell Lung Cancer Patients With Interstitial Lung Disease

Journal of Thoracic Oncology

English

P1.01-102 Retrospective Analysis of Immune Checkpoint Inhibitors in Patients With EGFR Mutated Non-Small Cell Lung Cancer in a Japanese Cohort

Journal of Thoracic Oncology

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by R. Shiga

P1.01-41 a Phase 2 Study of DS-8201a in HER2-Overexpressing or -Mutated Advanced Non-Small-Cell Lung Cancer

Related publications

OA02.07 Updated Results of Phase 1 Study of DS-8201a in HER2-Expressing or –Mutated Advanced Non-Small-Cell Lung Cancer

P1.01-13 a Study of S-1 Plus Cisplatin in Patients With Advanced Non-Small-Cell Lung Cancer

P1.01-91 a Phase I Study of Fixed Dose Vinorelbine and Escalating Doses of Ifosfamide in First-Line Advanced Non-Small Cell Lung Cancer

P1.01-19 Efficacy of Tyrosine Kinase Inhibitors in EGFR Mutated Non-Small Cell Lung Cancer With Leptomeningeal Metastases

P1.01-71 Co-Mutations, Natural History, and Outcomes of BRAF-Mutated Non-Small Cell Lung Cancer at a Single Academic Cancer Center

P1.01-109 Phase I Study of Apatinib Plus Gefitinib as First-Line Therapy in Patients With EGFR Mutant Advanced Non-Small Cell Lung Cancer

P1.01-47 Phase I/Ii Trial of Dasatinib and Osimertinib in Patients With Advanced EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)

P1.01-32 a Multicenter, Open-Label, Phase II Trial of S-1 Plus Carboplatin in Advanced Non-Small Cell Lung Cancer Patients With Interstitial Lung Disease

P1.01-102 Retrospective Analysis of Immune Checkpoint Inhibitors in Patients With EGFR Mutated Non-Small Cell Lung Cancer in a Japanese Cohort